Description: CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Home Page: www.curevac.com
CVAC Technical Analysis
Friedrich-Miescher-Strasse 15
Tübingen,
72076
Germany
Phone:
49 7071 9883 0
Officers
| Name | Title |
|---|---|
| Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D. | CEO, Member of Management Board & MD |
| Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board |
| Dr. Igor Splawski M.Sc., Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. Antony Blanc Ph.D. | MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board |
| Mr. Malte Greune Ph.D. | COO, Member of Management Board & MD |
| Dr. Sarah Fakih | VP Corp. Communications & Investor Relations |
| Mr. Marco Rau L.L.M., Ph.D. | Gen. Counsel |
| Mr. Thorsten Schuller | Head of Corp. Communications |
| Slavica Stevanovic-Heck | Head of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 9.1659 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0711 |
| Price-to-Sales TTM: | 13.2866 |
| IPO Date: | 2020-08-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 764 |